MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of marketable...
$48,802K
Proceeds from exercise of
stock options
$5,025K
Proceeds from capital
contributions for digital...
$2,475K
Net cash provided by
investing activities
$9,143K
Cash provided by
financing activities
$7,500K
Canceled cashflow
$39,659K
Net increase in
cash, cash...
$7,106K
Canceled cashflow
$9,537K
Purchases of marketable
securities
$38,863K
Purchases of property and
equipment
$796K
Share-based compensation
expense
$11,928K
Deferred revenue
$4,004K
Depreciation expense
$3,418K
Accounts receivable, net
-$2,050K
Noncash lease expense
$1,448K
Intangible assets
amortization
$419K
Impairment of long-lived
assets
$347K
Other Noncash Income
Expense
-$14K
Net cash used in
operating activities
-$9,537K
Canceled cashflow
$23,628K
Net loss
-$20,015K
Accounts payable and
accrued liabilities
-$7,512K
Operating lease
right-of-use assets and...
-$2,600K
Inventory
$1,315K
Prepaid expenses and
other current assets
$824K
Revenue interest
purchase agreement...
$655K
Investment amortization
$136K
Increase Decrease In
Other Operating...
$98K
Write-off of inventory
-$10K
Back
Back
Cash Flow
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (ADPT)
source: myfinsight.com